Today's Must Read
Oracle (ORCL) to Buy Ad Verification Software Maker Moat
Merck's (MRK) New Drugs to Drive Sales; Generic Pressures Stay
Wednesday April 19, 2017
Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway (BRK.B), Oracle (ORCL) and Merck (MRK).
Berkshire Hathaway's shares have lost ground lately, with the stock lagging the broader market since March 1st. The stock has also fallen behind the S&P 500 and the Zacks Finance sector. The insurance business, which remains at the core of this financial conglomerate's business portfolio, is as much a beneficiary of the post-election momentum in interest rates as are traditional banks and brokers. But Berkshire Hathaway is more than insurance - it has assets in the railroads, oil pipelines and many other spaces.
Investment in Apple (increasing its stake fourfold) and in the four biggest U.S. airlines (increased sevenfold) is testimony to the confidence in the post-election business environment. The company's name has long been synonymous with Warren Buffet, concerns about whose succession have been an issue for the stock. The company is expected to report first quarter results on May 5th. (You can read the full research report on Berkshire Hathaway here.)
Shares of Oracle has outperformed the Zacks Technology Sector year-to-date, gaining +15.8% vs. +8.1%. The company’s offerings in SaaS and PaaS have gained significant momentum in the past few quarters, which improves competitive position against salesforce.com and Workday. The introduction of Gen 2 IaaS data centers is expected to improve Oracle’s competitive prowess against Amazon.
The Zacks analyst likes the company’s growing cloud market share and believes it will continue to drive top-line growth for the foreseeable future. The recent acquisition of Moat is a significant addition to the Oracle Data Cloud, which will boost ad measurement capability. However, the transition from on-premise licensing to cloud-based subscription business model will take some more time to complete, which will impact near-term results. (You can read the full research report on Oracle here.)
Merck’s shares have gained +10% over the last one year, outperforming the Zacks Large Cap Pharma industry which has lost -2.7% over the same period. The Zacks analyst likes Merck’s new products, especially Keytruda, which should continue to contribute meaningfully to the top line. Merck will continue to focus on cost-cutting initiatives to drive the bottom line.
The company has also made significant progress with its pipeline and is working on bringing new products to the market. Merck has also been pursuing acquisitions and business development deals to boost its pipeline. However, generic competition and pricing pressure will continue to pressurize the top line. Merck will continue to focus on cost-cutting initiatives to drive the bottom line. The company has also made significant progress with its pipeline and is working on bringing new products to the market.
However, generic competition and pricing pressure will continue to pressurize the top line. Estimates have gone up ahead of the company’s Q1 earnings release. Merck has a positive record of earnings surprises in the recent quarters. (You can read the full research report on Merck here.)
Other noteworthy reports we are featuring today include DuPont (DD), Honeywell (HON) and Altria (MO).
Today's Private Buys & Sells from Zacks Research
While we share the above news with the public, our sensitive recommendations are hidden from everyone but selected members. Would you like to peek behind the curtain and view them? Starting today, for the next month, you can follow all Zacks' private buys and sells in real time from value to momentum . . . from stocks under $10 to ETF and option moves . . . from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors. Click here for Zacks' secret trades >>
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here >>>